255 related articles for article (PubMed ID: 17493521)
1. Not all "quality-adjusted life years" are equal.
Marra CA; Marion SA; Guh DP; Najafzadeh M; Wolfe F; Esdaile JM; Clarke AE; Gignac MA; Anis AH
J Clin Epidemiol; 2007 Jun; 60(6):616-24. PubMed ID: 17493521
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis.
van den Hout WB; Goekoop-Ruiterman YP; Allaart CF; de Vries-Bouwstra JK; Hazes JM; Kerstens PJ; van Zeben D; Hulsmans HM; de Jonge-Bok JM; de Sonnaville PB; Dijkmans BA; Breedveld FC
Arthritis Rheum; 2009 Mar; 61(3):291-9. PubMed ID: 19248130
[TBL] [Abstract][Full Text] [Related]
3. A view from the bridge: agreement between the SF-6D utility algorithm and the Health Utilities Index.
O'Brien BJ; Spath M; Blackhouse G; Severens JL; Dorian P; Brazier J
Health Econ; 2003 Nov; 12(11):975-81. PubMed ID: 14601159
[TBL] [Abstract][Full Text] [Related]
4. Cost-utility and cost-effectiveness analyses of a long-term, high-intensity exercise program compared with conventional physical therapy in patients with rheumatoid arthritis.
van den Hout WB; de Jong Z; Munneke M; Hazes JM; Breedveld FC; Vliet Vlieland TP
Arthritis Rheum; 2005 Feb; 53(1):39-47. PubMed ID: 15696568
[TBL] [Abstract][Full Text] [Related]
5. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis.
Marra CA; Woolcott JC; Kopec JA; Shojania K; Offer R; Brazier JE; Esdaile JM; Anis AH
Soc Sci Med; 2005 Apr; 60(7):1571-82. PubMed ID: 15652688
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial.
Kobelt G; Lindgren P; Singh A; Klareskog L
Ann Rheum Dis; 2005 Aug; 64(8):1174-9. PubMed ID: 15708879
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden.
Bansback NJ; Brennan A; Ghatnekar O
Ann Rheum Dis; 2005 Jul; 64(7):995-1002. PubMed ID: 15550533
[TBL] [Abstract][Full Text] [Related]
8. Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective.
Schipper LG; Kievit W; den Broeder AA; van der Laar MA; Adang EM; Fransen J; van Riel PL
Rheumatology (Oxford); 2011 Jul; 50(7):1320-30. PubMed ID: 21371999
[TBL] [Abstract][Full Text] [Related]
9. Assessing utility values in rheumatoid arthritis: a comparison between time trade-off and the EuroQol.
Ariza-Ariza R; Hernández-Cruz B; Carmona L; Dolores Ruiz-Montesinos M; Ballina J; Navarro-Sarabia F;
Arthritis Rheum; 2006 Oct; 55(5):751-6. PubMed ID: 17013822
[TBL] [Abstract][Full Text] [Related]
10. Medico-economic evaluation of infliximab in rheumatoid arthritis--prospective French study of a cohort of 635 patients monitored for two years.
Sany J; Cohen JD; Combescure C; Bozonnat MC; Roch-Bras F; Lafon G; Daurès JP
Rheumatology (Oxford); 2009 Oct; 48(10):1236-41. PubMed ID: 19620209
[TBL] [Abstract][Full Text] [Related]
11. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.
Karlsson JA; Neovius M; Nilsson JÅ; Petersson IF; Bratt J; van Vollenhoven RF; Ernestam S; Geborek P
Ann Rheum Dis; 2013 Dec; 72(12):1927-33. PubMed ID: 23196701
[TBL] [Abstract][Full Text] [Related]
12. A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia.
McCrone P; Patel A; Knapp M; Schene A; Koeter M; Amaddeo F; Ruggeri M; Giessler A; Puschner B; Thornicroft G
J Ment Health Policy Econ; 2009 Mar; 12(1):27-31. PubMed ID: 19346564
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the EuroQol and short form 6D in Singapore multiethnic Asian knee osteoarthritis patients scheduled for total knee replacement.
Xie F; Li SC; Luo N; Lo NN; Yeo SJ; Yang KY; Fong KY; Thumboo J
Arthritis Rheum; 2007 Aug; 57(6):1043-9. PubMed ID: 17665466
[TBL] [Abstract][Full Text] [Related]
14. Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden.
Lindgren P; Geborek P; Kobelt G
Int J Technol Assess Health Care; 2009 Apr; 25(2):181-9. PubMed ID: 19331709
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Markov model study based on two longitudinal observational studies.
Kvamme MK; Lie E; Uhlig T; Moger TA; Kvien TK; Kristiansen IS
Rheumatology (Oxford); 2015 Jul; 54(7):1226-35. PubMed ID: 25573840
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden.
Lekander I; Borgström F; Svarvar P; Ljung T; Carli C; van Vollenhoven RF
Int J Technol Assess Health Care; 2010 Jan; 26(1):54-61. PubMed ID: 20059781
[TBL] [Abstract][Full Text] [Related]
17. Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands.
Welsing PM; Severens JL; Hartman M; van Riel PL; Laan RF
Arthritis Rheum; 2004 Dec; 51(6):964-73. PubMed ID: 15593319
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate.
Vera-Llonch M; Massarotti E; Wolfe F; Shadick N; Westhovens R; Sofrygin O; Maclean R; Yuan Y; Oster G
Rheumatology (Oxford); 2008 Apr; 47(4):535-41. PubMed ID: 18356179
[TBL] [Abstract][Full Text] [Related]
19. Long-term followup of health status in patients with severe rheumatoid arthritis after high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation.
Teng YK; Verburg RJ; Sont JK; van den Hout WB; Breedveld FC; van Laar JM
Arthritis Rheum; 2005 Aug; 52(8):2272-6. PubMed ID: 16052541
[TBL] [Abstract][Full Text] [Related]
20. Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States.
Yuan Y; Trivedi D; Maclean R; Rosenblatt L
J Med Econ; 2010 Mar; 13(1):33-41. PubMed ID: 20001596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]